Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

| More on:
Two brokers analysing stocks.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It was another busy week for Australia's top brokers. This has led to the release of a number of broker notes.

Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX shares are in the buy zone:

CSL Ltd (ASX: CSL)

According to a note out of Morgan Stanley, its analysts have retained their overweight rating and $303.00 price target on this biotherapeutics company's shares. This follows news that CSL has received US Food & Drug Administration (FDA) approval for its Andembry therapy. This product aims to help prevent attacks of hereditary angioedema (HAE). While Morgan Stanley was pleased with the news, the broker was expecting its approval and had already factored it into its forecasts. Outside this, Morgan Stanley is forecasting low-teen annual earnings growth through to FY 2028. But it sees potential to accelerate this growth through a combination of lower costs and share buybacks. The CSL share price ended last week at $240.21.

Life360 Inc (ASX: 360)

Another note out of Morgan Stanley reveals that its analysts have retained their overweight rating on this location technology company's shares with an increased price target of $40.00. According to the note, the broker believes that Life360 is well-positioned to deliver further strong growth over the medium term. It highlights that it has one of the fast-growing userbases and is supported by the network effect and word of mouth. The latter should be supportive of lower customer acquisition costs compared to what other companies have to pay. Overall, in light of the above, the broker sees potential for Life360 to outperform the market's expectations in the medium term. The Life360 share price was fetching $31.94 at the end of last week.

Zip Co Ltd (ASX: ZIP)

Analysts at Ord Minnett have retained their buy rating on this buy now pay later provider's shares with an increased price target of $3.40. According to the note, the broker believes that Zip is in a great place right now following its second guidance update in less than three months. Ord Minnett is particularly pleased with the strong momentum that is being seen in the United States market. This is despite operating in a challenging macro environment. Together with the benefits of falling interest rates, the broker feels very positive about the company's outlook and believes it strong form can continue. The Zip share price was trading at $2.87 when the market closed on Friday.

Motley Fool contributor James Mickleboro has positions in CSL and Life360. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Life360, and Zip Co. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A male sharemarket analyst sits at his desk looking intently at his laptop with two other monitors next to him showing stock price movements
Broker Notes

Top brokers name 3 ASX shares to buy today

Here's what brokers are recommending as buys this week.

Read more »

A wad of $100 bills of Australian currency lies stashed in a bird's nest.
Broker Notes

Up 40% in a year, why Macquarie expects this ASX 200 dividend stock to keep outperforming in 2026

Macquarie forecasts more outperformance from this fast-rising ASX 200 dividend stock.

Read more »

A man wearing glasses and a white t-shirt pumps his fists in the air looking excited and happy about the rising OBX share price
Broker Notes

These ASX 200 shares could rise 30% to 40%

Looking for big returns? Bell Potter thinks these shares could be the ones to buy.

Read more »

Man standing on the roof rack of a van next to boxes and gear
Broker Notes

Broker tips 30% upside for this ASX 200 stock

This ASX 200 stock could now be a buy-low option.

Read more »

Broker looking at the share price.
Broker Notes

Broker ratings on 6 ASX shares about to join the ASX 200

These 6 companies will enter the ASX 200 in the December quarter rebalance. Should you buy them?

Read more »

A happy elderly woman smiles and cheers as she looks at good investment news on her laptop.
Broker Notes

Macquarie forecasts this $3.4 billon ASX healthcare share is set surge 33%

Macquarie tips material outperformance from this ASX healthcare share in 2026.

Read more »

Man looking at digital holograms of graphs, charts, and data.
Broker Notes

3 reasons this ASX 300 tech stock is forecast to leap 83% in 2026

A leading broker expects some outsized returns from this ASX 300 tech share. Let’s see why.

Read more »

gold share price represented by speeding golden bullet
Broker Notes

Why this surging ASX All Ords gold stock is tipped to rocket another 233%

A leading broker expects outsized gains from this ASX All Ords gold stock. But not without risk.

Read more »